A Pyrosequencing Assay for the Quantitative Methylation Analysis of GALR1 in Endometrial Samples: Preliminary Results

• Published in: BioMed research international Vol. 2015; no. 2015; pp. 1 - 6
• Main Authors: Pouliakis, Abraham, Panayiotides, Ioannis, Karakitsos, Petros, Spathis, Aris, Chrelias, Charalampos, Pappas, Asimakis, Bilirakis, Evripidis, Terzakis, Emmanouil, Margari, Niki, Koureas, Nikolaos, Kottaridi, Christine, Aga, Evangelia
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2015; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Adult; Age; Aged; Aged, 80 and over; Biological assay; Cellular biology; Colleges & universities; Deoxyribonucleic acid; DNA; DNA - analysis; DNA - chemistry; DNA methylation; DNA Methylation - genetics; DNA sequencing; Endometrial cancer; Endometrial Neoplasms - genetics; Endometrium - chemistry; Female; Genes; Genetic aspects; Gynecology; Hospitals; Humans; Laboratories; Methods; Methylation; Middle Aged; Nucleotide sequencing; Observations; Obstetrics; Pathology; ROC Curve; Sequence Analysis, DNA - methods
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2015/756359

Endometrial cancer is the most common malignancy of the female genital tract while aberrant DNA methylation seems to play a critical role in endometrial carcinogenesis. Galanin’s expression has been involved in many cancers. We developed a new pyrosequencing assay that quantifies DNA methylation of galanin’s receptor-1 (GALR1). In this study, the preliminary results indicate that pyrosequencing methylation analysis of GALR1 promoter can be a useful ancillary marker to cytology as the histological status can successfully predict. This marker has the potential to lead towards better management of women with endometrial lesions and eventually reduce unnecessary interventions. In addition it can provide early warning for women with negative cytological result.